Heart failure (HF) causes a heavy disease burden globally. Identifying etiological risk factors is essential for informing disease prevention and developing new treatment strategies. This review synthesizes insights from published Mendelian randomization (MR) studies on risk factors associated with HF. MR analyses support potential causal associations between various risk factors and HF, including lifestyle habits (e.g., physical activity, smoking, and sleep patterns), cardiometabolic factors (e.g., obesity, hypertension, type 2 diabetes, and dyslipidemia), nutritional exposures (e.g., 25-hydroxyvitamin D, sodium intake, and diet), emerging biomarkers (e.g., fibroblast growth factor 23), gut microbiota, and potential druggable targets. These studies uncover molecular processes that may contribute to HF pathogenesis and provide leads for therapeutic intervention. However, findings are not always consistent across studies, and discrepancies may arise from differences in study design, genetic instruments, population characteristics, and analytical methods. Key assumptions, including the absence of horizontal pleiotropy and the validity of instrumental variables, may not always be fully satisfied, since the interpretation of MR results requires caution. Future MR studies integrating multiomics data, advanced methodologies, and diverse populations will be essential to refine causal inference and enhance translational relevance. Overall, MR provides valuable insights into the potential causal determinants of HF and may contribute to improved prevention strategies and identification of therapeutic targets, although further validation and integration with clinical evidence are required.
Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality and disability worldwide. Asia bears a disproportionate share of this burden, with substantial heterogeneity across subregions.
Methods: Using data from the Global Burden of Disease (GBD) 2023 Study, we assessed the burden of CVDs in Asia and its subregions from 1990 to 2023, including prevalence, deaths, and disability-adjusted life years (DALYs), stratified by age and sex. Temporal trends were evaluated using Joinpoint regression, and decomposition analysis was performed to quantify the contributions of population growth, aging, and epidemiological changes. Population attributable fractions of level 2 risk factors and rankings of the most detailed risk exposures were assessed across subregions. Estimates for prevalence, deaths, DALYs, and population attributable fractions with corresponding 95% uncertainty intervals (UI) were derived.
Results: From 1990 to 2023, age-standardized mortality rates (ASMR) and age-standardized DALY rates (ASDR) declined across all Asian subregions, whereas age-standardized prevalence rates remained stable or increased in several regions. Joinpoint regression analysis revealed transient increases in ASMR and ASDR during specific periods in certain subregions. In 2023, East Asia had the largest absolute burden (140.5 million cases [95% UI: 130.7–152.8]; 4.7 million deaths [95% UI: 4.1–5.2]), while South Asia recorded the highest DALYs (102.3 million [95% UI: 90.6–113.5]). Central Asia exhibited the highest age-standardized rates (ASMR: 400.7 [95% UI: 374.0–418.6]; ASDR: 8,111.4 [95% UI: 7,734.2–8,421.9] per 100,000), whereas high-income Asia Pacific had the lowest. Despite the declines in age-standardized rates, absolute CVD deaths increased in all subregions, with decomposition analysis showing this rise was primarily driven by population aging and population growth. Ischemic heart disease and stroke accounted for over 86% of deaths and DALYs in most subregions, with ischemic heart disease predominating in Central Asia and stroke contributing disproportionately in Southeast Asia. South Asia showed a notable burden of rheumatic heart disease, along with elevated early-life DALYs primarily driven by stroke and cardiomyopathy/myocarditis. Metabolic risk factors dominated across regions, with high systolic blood pressure and high low-density lipoprotein (LDL) cholesterol as the leading contributors.
Conclusions: Although age-standardized CVD mortality and DALYs have declined across Asia, the overall burden remains substantial and heterogeneous. Region-specific strategies targeting dominant risk factors are essential to effectively reduce CVD burden across diverse Asian populations.
Background: Patients with aortic valve disease with ascending aortic dilation (AAD) are not uncommon in clinical practice; however, currently, research on the prognosis of such patients after transcatheter aortic valve implantation (TAVI) surgery in the Asian region is still insufficient. We aimed to compare short-term outcomes and 3-year follow-up clinical outcomes in patients with aortic valve disease who underwent TAVI with or without AAD.
Methods: Patients with aortic valve disease who underwent TAVI at Beijing Anzhen Hospital between March 2017 and February 2024 were continuously enrolled and divided into dilated (maximum ascending aorta width ≥ 40 mm) and nondilated groups. The short-term results were analyzed using logistic regression. Kaplan–Meier curves illustrated the survival differences, and the log-rank test was used for evaluation. The independent risk factors affecting 3-year follow-up clinical outcomes were analyzed using a Cox regression model and restricted cubic spline (RCS) analysis. We used patient follow-up data to investigate the rate of progression of AAD.
Results: A total of 440 patients were included in this study, including 185 in the AAD group and 255 in the non-AAD group. There was no statistically significant difference in the perioperative complication rate or perioperative mortality between the two groups. The overlap of Kaplan–Meier curves was high in the two groups, and there was no difference in the log-rank test (P = 0.521). Restricted cubic spline analysis revealed a nonlinear relationship between age and valve size for predicting all-cause mortality (nonlinear coefficients = 0.0489 and 0.0194). The median follow-up time was 1,051 days (484, 1,541) in the non-AAD group and 961 days (488, 1,672) in the AAD group. Follow-up data showed that there was no significant difference in the rate of progression of AAD between the two groups: 0.44 mm/year (0, 1.60) in the non-AAD group and 0.47 (-0.03, 1.60) in the AAD group (P = 0.861). During the follow-up process, no patients in the whole cohort developed ascending aortic dissection.
Conclusions: This study found no significant difference in short-term outcomes or 3-year follow-up clinical outcomes between TAVI patients with AAD and those without; therefore, TAVI appears to be safe for patients with aortic valve disease accompanied by ascending aorta dilation. This study found that age, hospitalization length, and valve size may provide a new basis for the risk assessment of all-cause mortality in patients undergoing TAVI, suggesting that individualized management strategies should be developed for age, length of hospital stay, and valve size.
Background: Rising evidence indicates that several autoimmune rheumatic diseases (ARDs) are associated with a higher risk of heart failure (HF); however, large-scale comparative studies across multiple ARDs are scarce.
Methods: In this cohort study, participants without prevalent HF from the UK Biobank were included. The relation between ARDs and the incidence of HF and mortality was analyzed using Cox proportional hazards models.
Results: Of 499,525 participants included in this study (n = 10,198 with ARDs, n = 489,327 without ARDs), 18,686 HF cases occurred over a median follow-up of 13.8 years. Significantly elevated risks for HF were observed among all patients with ARDs (P < 0.05), with the highest relative risk of HF in patients with systemic sclerosis (hazard ratio [HR]: 4.38; 95% confidence interval [CI]: 2.98–6.43; P < 0.001). Of patients who developed HF, those with ARDs exhibited a higher prevalence of rheumatic valvular disease (16.6% vs. 14.0%), non-rheumatic aortic valve disease (12.6% vs. 9.6%), and pulmonary heart disease (7.0% vs. 4.6%) before the diagnosis of HF (P < 0.05), while the prevalence of coronary artery disease, atrial fibrillation/atrial flutter, and hypertensive heart disease was similar. A history of ARDs was associated with increased all-cause mortality after diagnosis of HF (HR: 1.32; 95% CI: 1.23–1.42; P < 0.001), especially for non-cardiovascular mortality (HR: 1.42; 95% CI: 1.30–1.56; P < 0.001).
Conclusion: Various ARDs were associated with a higher risk of HF. Patients with HF and ARDs had a higher prevalence of valvular disease and pulmonary heart disease before HF diagnosis compared with other patients with HF. A history of ARDs was associated with higher mortality after diagnosis of HF.
Background: Coronary slow flow (CSF) is characterized by reduced coronary circulation and delayed contrast media opacity during angiography. Inflammatory responses have been observed in CSF. The correlation between lipoprotein-associated phospholipase A2 (LpPLA2) as a vascular inflammatory factor and the prognosis of CSF patients remains unclear. This study aims to investigate the potential correlation between plasma LpPLA2 levels and the occurrence of major adverse cardiovascular events (MACE) in CSF patients.
Methods: A retrospective study was conducted on 285 patients with CSF who were admitted to Anqing Municipal Hospital from January 2019 to March 2023. LpPLA2 plasma levels and baseline data were collected from hospital records; the mean thrombolysis in myocardial infarction frame count (mTFC) was calculated for each patient. Follow-up was conducted by telephone call or cardiology clinic data, and the occurrence and timing of MACE were recorded.
Results: The median follow-up duration was 25 (95% confidence interval [CI]: 23–27) months. During follow-up, MACE occurred in 54 patients (18.9%), including 4 individuals who had nonfatal myocardial infarction, 6 who had arrhythmias (4 with atrial fibrillation, 2 with frequent ventricular premature beats), and 44 who had rehospitalizations due to unstable angina pectoris. No cardiac deaths or cerebrovascular events occurred during follow-up. We categorized LpPLA2 into quartiles, and multivariable adjusted Cox models showed an association between LpPLA2 levels and MACE incidence among CSF patients. Compared with the lowest quartiles, the hazard ratios for the highest quartiles of LpPLA2 levels were 2.77 (95% CI: 1.11–6.92) (P-trend < 0.01). Though the restricted cubic spline curve indicates a linear relationship between LpPLA2 and MACE incidence in patients with CSF (P for nonlinearity = 0.174), the risk of MACE was relatively flat until 247.7 ng/mL of predicted LpPLA2 levels and increased afterward, with an HR of 1.86 (95% CI: 1.27–2.82) per standard deviation. Kaplan–Meier survival assessments revealed that patients in the highest LpPLA2 quartile exhibited a worse prognosis for MACE compared with those in the lower quartiles of LpPLA2 levels (log-rank P = 0.002). Additionally, multivariable Cox regression analyses identified mTFC, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and diabetes as other factors associated with the occurrence of MACE in patients with CSF.
Conclusion: Elevated plasma LpPLA2 levels were associated with MACE (rehospitalization-dominated MACE) in patients with CSF after multivariable adjustment. In addition to LpPLA2, dyslipidemia, diabetes, and mTFC may also be correlated with the prognosis of CSF.
Trial registration: ChiCTR2400086042, June 24, 2024 (Retrospectively registered).